Predicting bone scan positivity after biochemical recurrence following radical prostatectomy in both hormone-naive men and patients receiving androgen-deprivation therapy: Results from the SEARCH database

Prostate Cancer and Prostatic Diseases

Volumn 17, Issue 1, 2014, Pages 91-96

  Moreira, D M ^a   Cooperberg, M R ^b   Howard, L E ^c,d   Aronson, W J ^b,e   Kane, C J ^f   Terris, M K ^d,g   Amling, C L ^h   Kuchibhatla, M ^c   Freedland, S J ^c,d  

^a The Arthur Smith Institute for Urology   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d DURHAM VA MEDICAL CENTER   (United States)

^e UCLA MEDICAL CENTER   (United States)

^f UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^g MEDICAL COLLEGE OF GEORGIA   (United States)

^h OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

disease free survival; metastasis; mortality; prostatectomy; PSA

Indexed keywords

ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; PROSTATE SPECIFIC ANTIGEN;

AGED; BONE; BONE NEOPLASMS; CANCER GRADING; CANCER STAGING; FACTUAL DATABASE; HUMAN; MALE; MIDDLE AGED; PATHOLOGY; PROGNOSIS; PROSTATECTOMY; PROSTATIC NEOPLASMS; RECURRENT DISEASE; RETROSPECTIVE STUDY; SECONDARY;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BONE AND BONES; BONE NEOPLASMS; DATABASES, FACTUAL; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RECURRENCE; RETROSPECTIVE STUDIES;

EID: 84894083618     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2013.59     Document Type: Article

References (23)

1. Palvolgyi R, Daskivich TJ, Chamie K, Kwan L, Litwin MS. Bone scan overuse in staging of prostate cancer: an analysis of a Veterans Affairs cohort. Urology 2011;77:1330-1336.
2. Moslehi M, Cheki M, Salehi-Marzijarani M, Amuchastegui T, Gholamrezanezhad A. Predictors of bone metastasis in pre-treatment staging of asymptomatic treatmentnaive patients with prostate cancer. Rev Esp Med Nucl Imagen Mol 2013;32:286-289.
3. De Nunzio C, Leonardo C, Franco G, Esperto F, Brassetti A, Simonelli G et al. When to perform bone scan in patients with newly diagnosed prostate cancer: external validation of a novel risk stratification tool. World J Urol 2013;31:365-369.
4. Ayyathurai R, Mahapatra R, Rajasundaram R, Srinivasan V, Archard NP, Toussi H. A study on staging bone scans in newly diagnosed prostate cancer. Urol Int 2006;76:209-212.
5. Ishizuka O, Tanabe T, Nakayama T, Kawakami M, Kinebuchi Y, Nishizawa O. Prostate-specific antigen, Gleason sum and clinical T stage for predicting the need for radionuclide bone scan for prostate cancer patients in Japan. Int J Urol 2005;12:728-732.
6. O'Sullivan JM, Norman AR, Cook GJ, Fisher C, Dearnaley DP. Broadening the criteria for avoiding staging bone scans in prostate cancer: a retrospective study of patients at the Royal Marsden Hospital. BJU Int 2003;92:685-689.
7. Ritenour CW, Abbott JT, Goodman M, Alazraki N, Marshall FF, Issa MM. The utilization of Gleason grade as the primary criterion for ordering nuclear bone scan in newly diagnosed prostate cancer patients. Scientific World J 2009;9:1040-1045.
8. Kosuda S, Yoshimura I, Aizawa T, Koizumi K, Akakura K, Kuyama J, Ichihara K et al. Can initial prostate specific antigen determinations eliminate the need for bone scans in patients with newly diagnosed prostate carcinoma? A multicenter retrospective study in Japan. Cancer 2002;94:964-972.
9. Lorente JA, Morote J, Raventos C, Encabo G, Valenzuela H. Clinical efficacy of bone alkaline phosphatase and prostate specific antigen in the diagnosis of bone metastasis in prostate cancer. J Urol 1996;155:1348-1351.
10. Wolff JM, Bares R, Jung PK, Buell U, Jakse G. Prostate-specific antigen as a marker of bone metastasis in patients with prostate cancer. Urol Int 1996;56:169-173.
11. Chybowski FM, Keller JJ, Bergstralh EJ, Oesterling JE. Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters. J Urol 1991;145:313-318.
12. Bruwer G, Heyns CF, Allen FJ. Influence of local tumour stage and grade on reliability of serum prostate-specific antigen in predicting skeletal metastases in patients with adenocarcinoma of the prostate. Eur Urol 1999;35:223-227.
13. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281:1591-1597.
14. Slovin SF, Wilton AS, Heller G, Scher HI. Time to detectable metastatic disease in patients with rising prostate-specific antigen values following surgery or radiation therapy. Clin Cancer Res 2005;11:8669-8673.
15. Okotie OT, Aronson WJ, Wieder JA, Liao Y, Dorey F, De KJ et al. Predictors of metastatic disease in men with biochemical failure following radical prostatectomy. J Urol 2004;171:2260-2264.
16. Dotan ZA, Bianco Jr. FJ, Rabbani F, Eastham JA, Fearn P, Scher HI et al. Pattern of prostate-specific antigen (PSA) failure dictates the probability of a positive bone scan in patients with an increasing PSA after radical prostatectomy. J Clin Oncol 2005;23:1962-1968.
17. Loeb S, Makarov DV, Schaeffer EM, Humphreys EB, Walsh PC. Prostate specific antigen at the initial diagnosis of metastasis to bone in patients after radical prostatectomy. J Urol 2010;184:157-161.
18. Smith MR, Kabbinavar F, Saad F, Hussain A, Gittelman MC, Bilhartz DL et al. Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol 2005;23:2918-2925.
19. Smith MR, Cook R, Lee KA, Nelson JB. Disease and host characteristics as predictors of time to first bone metastasis and death in men with progressive castration-resistant nonmetastatic prostate cancer. Cancer 2011;117:2077-2085.
20. Whitley BM, Moreira DM, Thomas JA, Aronson WJ, Terris MK, Presti Jr. JC et al. Preoperative weight change and risk of adverse outcome following radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital database. Prostate Cancer Prostatic Dis 2011;14:361-366.
21. Freedland SJ, Sutter ME, Dorey F, Aronson WJ. Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Prostate-specific antigen. Urology 2003;61:365-369.
22. Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 2005;294:433-439.
23. Sadik M, Suurkula M, Hoglund P, Jarund A, Edenbrandt L. Quality of planar wholebody bone scan interpretations-a nationwide survey. Eur J Nucl Med Mol Imaging 2008;35:1464-1472.